# A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

> **NCT02570308** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immunocore Ltd** · enrollment: 146 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** IMCgp100

## Key facts

- **NCT ID:** NCT02570308
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2020-03-20
- **Final completion:** 2022-10-17
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02570308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02570308, "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02570308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*